Atrial septal defect percutaneous closure: Difference between revisions
No edit summary |
No edit summary |
||
Line 1: | Line 1: | ||
{{ | {{Atrial septal defect}} | ||
{{CMG}} Claudia Hochberg, M.D. | {{CMG}} Claudia Hochberg, M.D. | ||
Line 5: | Line 5: | ||
'''Assistant Editor-In-Chief:''' [[Kristin Feeney|Kristin Feeney, B.S.]] [[mailto:kfeeney@perfuse.org]] | '''Assistant Editor-In-Chief:''' [[Kristin Feeney|Kristin Feeney, B.S.]] [[mailto:kfeeney@perfuse.org]] | ||
==Overview== | |||
Percutaneous transcatheter closure is used in limited atrial septal defect cases. The Food and Drug Administration has only authorized the use of percutaneous closure in [[Atrial septal defect ostium secundum|ostium secundum]] patients. | |||
==Percutaneous closure== | ==Percutaneous closure== | ||
Line 42: | Line 45: | ||
[[Category:Congenital heart disease]] | [[Category:Congenital heart disease]] | ||
[[Category:Pediatrics]] | [[Category:Pediatrics]] | ||
[[Category:Mature chapter]] | |||
{{WH}} | {{WH}} | ||
{{WS}} | {{WS}} |
Revision as of 01:31, 27 July 2011
Atrial Septal Defect Microchapters | |
Treatment | |
---|---|
Surgery | |
| |
Special Scenarios | |
Case Studies | |
Atrial septal defect percutaneous closure On the Web | |
American Roentgen Ray Society Images of Atrial septal defect percutaneous closure | |
Risk calculators and risk factors for Atrial septal defect percutaneous closure | |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Claudia Hochberg, M.D.
Associate Editors-In-Chief: Cafer Zorkun, M.D., Ph.D. [2]; Keri Shafer, M.D. [3]; Priyamvada Singh, MBBS [[4]]
Assistant Editor-In-Chief: Kristin Feeney, B.S. [[5]]
Overview
Percutaneous transcatheter closure is used in limited atrial septal defect cases. The Food and Drug Administration has only authorized the use of percutaneous closure in ostium secundum patients.
Percutaneous closure
Percutaneous transcatheter closure is current only indicated for the closure of ostium secundum atrial septal defects. It should not be used in patients with sinus venosus, primum or patent foramen ovale atrial septal defects. In patients with a secundum defect, there must be a sufficient rim of tissue around the septal defect.
The Food and Drug Administration has authorized the following percutaenous transcatheters for usage:[1]
- Amplatzer septal occluder
- CardioSEAL
- HELEX septal occluder
- Sideris patch
The Ampltazer septal occluder (ASO) is the most commonly used device as it allows closure of large cavities, is easy to implant, and boasts high success rates. As an instrument, the ASO consists of two self-expandable round discs connected to each other with a 4-mm waist, made up of 0.004–0.005´´ nitinol wire mesh filled with Dacron fabric. Implantation of the device is relatively easy. The prevalence of residual defect is low. The disadvantages are a thick profile of the device and concern related to a large amount of nitinol (a nickel-titanium compound) in the device and consequent potential for nickel toxicity.
<youtube v=Gros-u7YCTk/>
<youtube v=4c3CEgjj2PY/>
Evaluation
Benefits of percutaneous closure
Complications of percutaneous closure
References
- ↑ Schwetz BA (2002). "From the Food and Drug Administration". JAMA. 287 (5): 578. PMID 11829678.